Loading
companiesCompany
Candel Therapeutics
Candel makes viral immunotherapies injected into tumours to trigger an immune attack. Its lead product, aglatimagene, improved disease-free survival when added to radiotherapy in localised prostate cancer in a phase 3 trial, and a US approval filing is planned for late 2026.
Overview
Candel Therapeutics is a Needham, Massachusetts clinical-stage company developing multimodal viral immunotherapies. Lead candidate aglatimagene besadenovec (CAN-2409), an adenoviral immunotherapy, showed a statistically significant improvement in disease-free survival when added to standard radiotherapy in a pivotal phase 3 trial in localised, intermediate- to high-risk prostate cancer (published in The Lancet Oncology); a BLA submission is planned for the fourth quarter of 2026 with a potential US launch in 2027. The global pivotal phase 3 AURORA trial in stage IV non-squamous non-small cell lung cancer progressing on pembrolizumab has opened enrolment. CAN-3110 (linoserpaturev), an HSV-based oncolytic immunotherapy, is being planned for a randomised phase 2 trial in recurrent glioblastoma. Candel had $201.6 million in cash at 30 June 2026 with runway into the first quarter of 2028. Nasdaq: CADL.
Headquarters
Needham, MA, US
Scorecard
All companies#322of 1244 companies, score 12
- phase 3 +3
- modalities +2
- registry trials +7
0 approved, 1 in phase 3, 0 earlier, 0 targets, 12 registry studies. Formula on the scorecards page.
Type
Biotech · CADL
Stage
Public
Website
Phase 3gene therapy
Aglatimagene besadenovec is an experimental gene therapy from Candel Therapeutics in phase 3 trials for non-small-cell lung cancer and prostate cancer, with its target not yet stated publicly.
Notes
top- No funding round sourced.
Similar pages
- CompanyKopra Bio
Shares Oncolytic viruses, Glioma & glioblastoma.
- PersonTomoki Todo
Shares Oncolytic viruses, Glioma & glioblastoma.
- Key paperToca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work
Shares Oncolytic viruses, Glioma & glioblastoma.
- Key paperMartuza 1991: the first genetically engineered virus built to treat a cancer
Shares Oncolytic viruses, Glioma & glioblastoma.
- PersonRobert L. Martuza
Shares Oncolytic viruses, Glioma & glioblastoma.
- Key paperTodo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus
Shares Oncolytic viruses, Glioma & glioblastoma.
- IdeaDeliver drugs and cells to the brain through the nose
Shares Oncolytic viruses, Glioma & glioblastoma.
- InstitutionDuke Cancer Institute
Shares Oncolytic viruses, Glioma & glioblastoma, Prostate cancer.
cancers
fronts
technologies
drugs
Phase 3gene therapy
trials
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecAglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCPhase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerRandomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)